The medical technology company confirmed it is selling all 9.8 million shares included in the offering. Despite the offering price of $4.10 a share being set below the previous close, market demand pushed the stock price to $5.11, representing a double-digit gain for the session.

Terms of the Offering

As part of the agreement, TriSalus Life Sciences has granted the underwriter a 30-day option to purchase up to 1.5 million additional shares. This overallotment option represents 15% of the total offering and would be executed at the public offering price, less underwriting discounts and commissions.

The company anticipates total proceeds of $40 million before accounting for fees and other offering-related expenses. According to the official statement, the deal is scheduled to close on Monday, subject to standard settlement procedures.